← Leaderboards
Xingming Deng
University Of Florida
$11,809,682
Attributed
$11,809,682
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,809,682 · 7
By mechanism
R01$9,941,287 · 5
P50$1,868,395 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Weihong Tan$6,516,065
- Maryam Rahman$1,071,900
- William Stratford May$10,672,913
- Stephen Patrick Hunger$7,938,370
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungApoptoticNon-Small-Cell Lung CarcinomaResistanceTumor TissueSmall MoleculeCancer TherapyMutationMalignant NeoplasmsCancer CellPathway InteractionsSignal TransductionSiteApoptosisAntineoplastic AgentsGenetic EngineeringKras2 GeneIn VitroTherapeutic TargetXenograft ProcedureMapk3 GenePhosphorylationLeadNovel Strategies
Grant awards (36)
Modulation of Mcl-1 for Treatment of Lung Cancer$433,907
R01 · FY2025 · CA · contact PI
Modulation of Mcl-1 for Treatment of Lung Cancer$412,210
R01 · FY2024 · CA · contact PI
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC$128,039
P50 · FY2024 · CA · contact PI
Modulation of Mcl-1 for Treatment of Lung Cancer$425,230
R01 · FY2023 · CA · contact PI
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC$346,329
P50 · FY2023 · CA · contact PI
Modulation of Mcl-1 for Treatment of Lung Cancer$425,225
R01 · FY2022 · CA · contact PI
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC$364,713
P50 · FY2022 · CA · contact PI
Modulation of Mcl-1 for Treatment of Lung Cancer$433,488
R01 · FY2021 · CA · contact PI
Modulation of BAK in Lung Cancer Therapeutics$356,850
R01 · FY2021 · CA · contact PI
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC$338,910
P50 · FY2021 · CA · contact PI
Structure-based anti-cancer drug development$370,500
R01 · FY2020 · CA · contact PI
Modulation of BAK in Lung Cancer Therapeutics$356,850
R01 · FY2020 · CA · contact PI
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC$347,015
P50 · FY2020 · CA · contact PI
Structure-based anti-cancer drug development$359,385
R01 · FY2019 · CA · contact PI
Modulation of BAK in Lung Cancer Therapeutics$346,144
R01 · FY2019 · CA · contact PI
Modulation of Bcl2 BH4 and mTOR in lung cancer therapeutics$346,144
R01 · FY2019 · CA · contact PI
Project 3: Targeting Bax signaling to overcome treatment resistance in NSCLC$343,389
P50 · FY2019 · CA · contact PI
Structure-based anti-cancer drug development$370,500
R01 · FY2018 · CA · contact PI
Modulation of Bcl2 BH4 and mTOR in lung cancer therapeutics$356,850
R01 · FY2018 · CA · contact PI
Modulation of BAK in Lung Cancer Therapeutics$356,850
R01 · FY2018 · CA · contact PI
Structure-based anti-cancer drug development$370,500
R01 · FY2017 · CA · contact PI
Modulation of Bcl2 BH4 and mTOR in lung cancer therapeutics$356,850
R01 · FY2017 · CA · contact PI
Modulation of BAK in Lung Cancer Therapeutics$356,850
R01 · FY2017 · CA · contact PI
Structure-based anti-cancer drug development$370,500
R01 · FY2016 · CA · contact PI
Modulation of Bcl2 BH4 and mTOR in lung cancer therapeutics$356,850
R01 · FY2016 · CA · contact PI
Modulation of Bcl2 BH4 and mTOR in lung cancer therapeutics$356,850
R01 · FY2015 · CA · contact PI
Structure-based anti-cancer drug development$300,677
R01 · FY2014 · CA · contact PI
Structure-based anti-cancer drug development$291,378
R01 · FY2013 · CA · contact PI
Structure-based anti-cancer drug development$309,976
R01 · FY2012 · CA · contact PI
Structure-based anti-cancer drug development$309,976
R01 · FY2011 · CA · contact PI
Structure-based anti-cancer drug development$319,563
R01 · FY2010 · CA · contact PI
Nicotine/NNK Signaling in Human Lung Cancer Cells$203,328
R01 · FY2008 · CA · contact PI
Nicotine/NNK Signaling in Human Lung Cancer Cells$15,500
R01 · FY2008 · CA · contact PI
Nicotine/NNK Signaling in Human Lung Cancer Cells$217,978
R01 · FY2007 · CA · contact PI
Nicotine/NNK Signaling in Human Lung Cancer Cells$224,488
R01 · FY2006 · CA · contact PI
Nicotine/NNK Signaling in Human Lung Cancer Cells$229,890
R01 · FY2005 · CA